**Summary**
Abingdon Health plc, a leading international developer and manufacturer of rapid diagnostic <mark style="background-color:yellow">test</mark>s and med-tech solutions, announced that its ordinary shares will begin trading on the OTCQB Venture Market in the United States under the ticker symbol "ABDXF" starting next month. This move aims to increase accessibility for U.S. investors, enhance liquidity on the London Stock Exchanges AIM Market (where it trades as "ABDX"), and attract a broader investor base. The OTCQB listing incurs minimal additional reporting costs due to Abingdon Healths status as a Foreign Private Issuer.
The company highlighted its recent expansion in Madison, Wisconsin, which complements its UK operations and provides customers with geographic flexibility amid supply chain uncertainties. Executive Chairman Chris Hand emphasized the strategic importance of the OTCQB listing, particularly in the U.S., the world’s largest lateral flow and med-tech market. Abingdon Health continues to focus on its CDMO services, regulatory support, and manufacturing capabilities, catering to sectors like infectious disease, animal health, and environmental testing.
Founded in 2008, Abingdon Health operates from its headquarters in York, UK, with additional facilities in Doncaster, UK, and Madison, Wisconsin, USA. The company remains committed to supporting its international customers from concept to commercial success.
**Key Points**
1. **OTCQB Listing** Abingdon Health shares to trade on the OTCQB Venture Market in the U.S. under "ABDXF."
2. **Strategic Expansion** U.S. facility expansion in Madison, Wisconsin, enhances manufacturing capabilities and customer options.
3. **Investor Accessibility** Aims to attract U.S. investors and increase liquidity on AIM.
4. **Minimal Reporting Costs** Exempt from additional SEC reporting as a Foreign Private Issuer.
5. **Global Reach** Focus on CDMO services, regulatory support, and manufacturing for international customers.